Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1986 Jan;51(1):6–9. doi: 10.1128/iai.51.1.6-9.1986

Activation of the alternative complement pathway by Sporothrix schenckii.

E N Scott, H G Muchmore, D P Fine
PMCID: PMC261057  PMID: 3941005

Abstract

We studied the activation of complement by Sporothrix schenckii yeast cells. Total complement activity, and the effect of various activators on this activity, were assayed on aliquots of fresh nonimmune human serum with and without prior treatment with chelators. Both total hemolytic complement and C3 were consumed (activated) in serum chelated with magnesium ethylene glycol-bis(beta-aminoethyl ether)-N,N,N',N'-tetraacetic acid, which blocks the classical pathway but leaves the alternative pathway intact. Further, C3 was consumed, but C4 (exclusively a component of the classical pathway) was preserved, in nonchelated serum after challenge by S. schenckii yeast cells. Absorption of serum with S. schenckii yeast cells to deplete antibodies did not alter these results. Furthermore, immunofluorescence studies demonstrated that C3, but not immunoglobulin G, was deposited on yeast cells during incubation with nonimmune serum. These data indicate that S. schenckii yeast cells activate the alternative complement pathway in vitro independently of antibody. These data do not define a role for the alternative pathway in in vivo host defenses against infection with this organism but provide a foundation for studies to evaluate such a role.

Full text

PDF
6

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Diamond R. D., May J. E., Kane M. A., Frank M. M., Bennett J. E. The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection. J Immunol. 1974 Jun;112(6):2260–2270. [PubMed] [Google Scholar]
  2. Fine D. P. Comparison of ethyleneglycoltetraacetic acid and its magnesium salt as reagents for studying alternative complement pathway function. Infect Immun. 1977 Apr;16(1):124–128. doi: 10.1128/iai.16.1.124-128.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fine D. P., Marney S. R., Jr, Colley D. G., Sergent J. S., Des Prez R. M. C3 shunt activation in human serum chelated with EGTA. J Immunol. 1972 Oct;109(4):807–809. [PubMed] [Google Scholar]
  4. Fine D. P. Pneumococcal type-associated variability in alternate complement pathway activation. Infect Immun. 1975 Oct;12(4):772–778. doi: 10.1128/iai.12.4.772-778.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Frank M. M. The complement system in host defense and inflammation. Rev Infect Dis. 1979 May-Jun;1(3):483–501. doi: 10.1093/clinids/1.3.483. [DOI] [PubMed] [Google Scholar]
  6. Geha R. S. Circulating immune complexes and activation of the complement sequence in acute allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol. 1977 Dec;60(6):357–359. doi: 10.1016/0091-6749(77)90066-5. [DOI] [PubMed] [Google Scholar]
  7. Gelfand J. A., Hurley D. L., Fauci A. S., Frank M. M. Role of complement in host defense against experimental disseminated candidiasis. J Infect Dis. 1978 Jul;138(1):9–16. doi: 10.1093/infdis/138.1.9. [DOI] [PubMed] [Google Scholar]
  8. Graybill J. R., Ahrens J. Immunization and complement interaction in host defense against murine Cryptococcosis. J Reticuloendothel Soc. 1981 Nov;30(5):347–357. [PubMed] [Google Scholar]
  9. Hachisuka H., Sasai Y. Development of experimental sporotrichosis in normal and modified animals. Mycopathologia. 1981 Nov 11;76(2):79–82. doi: 10.1007/BF00443754. [DOI] [PubMed] [Google Scholar]
  10. Laxalt K. A., Kozel T. R. Chemotaxigenesis and activation of the alternative complement pathway by encapsulated and non-encapsulated Cryptococcus neoformans. Infect Immun. 1979 Nov;26(2):435–440. doi: 10.1128/iai.26.2.435-440.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ratnoff W. D., Pepple J. M., Winkelstein J. A. Activation of the alternative complement pathway by Histoplasma capsulatum. Infect Immun. 1980 Oct;30(1):147–149. doi: 10.1128/iai.30.1.147-149.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Swan J. W., Dahl M. V., Coppo P. A., Hammerschmidt D. E. Complement activation by trichophyton rubrum. J Invest Dermatol. 1983 Mar;80(3):156–158. doi: 10.1111/1523-1747.ep12533147. [DOI] [PubMed] [Google Scholar]
  13. Torinuki W., Okohchi K., Takematsu H., Tagami H. Activation of the alternative complement pathway by Fonsecaea pedrosoi. J Invest Dermatol. 1984 Oct;83(4):308–310. doi: 10.1111/1523-1747.ep12340435. [DOI] [PubMed] [Google Scholar]
  14. Torinuki W., Tagami H. Complement activation by Sporothrix schenckii. Arch Dermatol Res. 1985;277(4):332–333. doi: 10.1007/BF00509093. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES